Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10150557 | 0.87 | DHFR (0.33) | DHFR | |
| SCHEMBL10150520 | 0.80 | DHFR (0.39) | DHFR | |
| SCHEMBL16158819 | 0.79 | STING1 (0.33) | — | |
| SCHEMBL16158835 | 0.68 | RXFP1 (0.33) | — | |
| SCHEMBL17732553 | 0.64 | ALDH1A1 (0.38) | — | |
| SCHEMBL16158115 | 0.64 | TK1 (0.36) | — | |
| SCHEMBL10239450 | 0.63 | DHFR (0.64) | DHFR | |
| SCHEMBL19749043 | 0.62 | LMNA (0.32) | — | |
| SCHEMBL16158818 | 0.62 | TDP1 (0.34) | — | |
| SCHEMBL16158849 | 0.62 | PDE4A (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170002037-A1 | CYCLIC NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. | 2017-01-05 | — | — | US | disclosed |
| US-8772474-B2 | Cyclic nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20120165286-A1 | CYCLIC NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170002037-A1 | CYCLIC NUCLEOTIDE ANALOGS | NT5C2, NTPCR, PNP | DHFR 363/4885 |
| US-20120165286-A1 | CYCLIC NUCLEOTIDE ANALOGS | NT5C2, NTPCR, PNP | DHFR 363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.